The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase 2 IDeate-Lung01 study.
Ifinatamab deruxtecan shows promising results in advanced small cell lung cancer
- Post author:
- Post published:September 9, 2024
- Post category:uncategorized